Cannabis stocks experienced a dramatic reversal of fortunes on Monday afternoon, with shares plummeting as hopes surrounding a potential executive order from President Donald Trump regarding marijuana’s classification faded. The initial surge of optimism, fueled by reports suggesting a shift from Schedule I to Schedule III, quickly dissipated, leading to significant losses across several prominent cannabis companies. This sudden downturn highlights the volatile nature of the sector and the intense sensitivity of investor sentiment to regulatory developments. The ongoing debate regarding marijuana’s status at the federal level continues to exert a powerful influence on market valuations, creating periods of intense speculation and, subsequently, sharp corrections.
The day’s trading began with considerable enthusiasm, driven by reports circulating late last week indicating President Trump was considering an executive order aimed at reclassifying marijuana. These reports suggested a move from Schedule I – which currently designates marijuana as having a high potential for abuse and no accepted medical use – to Schedule III. Schedule III drugs, which include certain steroids, are considered to have a lower potential for abuse than Schedule I drugs and are subject to less stringent regulations. This potential shift had a profound impact on the cannabis industry, as it would address several key concerns. A reduction in the drug’s classification would significantly impact cannabis companies, allowing them to reduce their financial and regulatory pressures. Furthermore, it would open the door to more relaxed banking restrictions, currently a substantial hurdle for the industry. Investors anticipated that a change could unlock previously unavailable access to capital and address the issues of accepting credit card payments, which remains a significant challenge for legal cannabis businesses.
Several key players in the cannabis sector experienced notable declines following the diminished prospects of the executive order. Tilray Brands (TLRY) saw its shares drop by nearly 5% in recent trading, reflecting the broader sentiment across the industry. The stock’s performance is particularly noteworthy given its previously strong performance and its position as one of the leading cannabis companies. Canopy Growth (CGC) also experienced a considerable slide, with its shares slipping by approximately 3%. This decline mirrored the trajectory of other cannabis stocks, demonstrating the interconnectedness of the industry’s valuation. Investors reacted negatively to a lack of concrete confirmation of the executive order, triggering a sell-off that erased earlier gains. The substantial losses underscore the vulnerability of the stock to regulatory uncertainty.
The potential reclassification of marijuana to Schedule III holds considerable implications for the cannabis industry. Currently, federal laws restrict research on marijuana’s medicinal properties due to its Schedule I classification. This limitation hinders the development of new treatments and limits the scientific understanding of marijuana’s potential benefits. A move to Schedule III would alleviate these restrictions, enabling more extensive research and potentially leading to the approval of marijuana-based pharmaceuticals. Beyond research, regulatory changes associated with Schedule III would address numerous challenges facing the industry, primarily the issue of banking. Financial institutions are hesitant to work with cannabis businesses due to federal illegality, making it difficult to obtain loans, accept payments, and manage finances.
The immediate impact of this news highlights the sensitivity of investor sentiment within the cannabis sector. The market’s responsiveness demonstrates a deep concern about regulatory developments and their potential impact on corporate valuations. While marijuana has achieved legal recognition on the state level for medicinal and recreational use, its continued federal illegality remains a core obstacle. The stock performance of Tilray and Canopy Growth, along with the broader market declines, indicates that the industry is heavily reliant on federal policy changes to drive significant growth and investment. Investors are keenly watching for any progress on federal reform, recognizing that a favorable policy shift could unlock substantial value within the cannabis sector.
As of today’s trading, Tilray Brands have experienced a decline of approximately 15% in 2025, reflecting the ongoing volatility of the stock. Canopy Growth shares, likewise, have diminished by nearly 40% of their value, illustrating the heightened sensitivity to regulatory news. This article has been updated since its initial publication to incorporate the most recent developments in this continuously evolving narrative. The cannabis industry remains tightly linked to political and regulatory processes. The potential executive order, while unconfirmed at the time of this writing, served as a stark reminder of the significant influence these factors have on the valuations and future prospects of cannabis companies.